Responds To Solicitation from Northeast Biodefense Center to
Develop Oral Formulation of its Proprietary Live Listeria Technology
TARGET: Oral Vaccine Immunizing Large...
Compositions and Methods for Enhancing Immunogenicity of Antigens
The US Patent and Trademark office approved Advaxis
Incorporated (OTCBB: ADXS) patent-application...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS), a biotechnology company developing novel Listeria-based therapeutic cancer vaccines, has been profiled in both...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has received confirmation that the
Gynecologic Oncology Group (GOG), a therapeutic clinical research group
of the...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) a biotechnology company developing novel Listeria-based
therapeutic cancer vaccines, announced that its Board of Directors...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS)
has completed the enrollment and dosing of the first cohort of patients
diagnosed with advanced, recurrent or...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) will participate at Rodman & Renshaw’s
8th Annual Healthcare Conference taking
place November 6 - 8,...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has conducted a pre-IND meeting with the
U.S. Food and Drug Administration (FDA) regarding its two planned Phase
II...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Sept. 11, 2006--Advaxis (OTCBB: ADXS) has appointed Thomas A. Moore, former President and Chief Executive Officer of Nelson Communications, Inc., Biopure...
PRINCETON, N.J.--(BUSINESS WIRE)--Dec. 12, 2005--Two leading biotech publications reported that Advaxis, Inc. (ADXS.OB) successfully demonstrated in testing of mice at the University of...
#8: ADXS News Advaxis, Inc. and Cobra Biomanufacturing Plc Enter a Strategic Collaboration and Long-Term Vaccine Supply Agreement for Listeria Cancer Vaccines
PRINCETON N.J.--(BUSINESS WIRE)--Nov. 7, 2005--Advaxis, Inc. (OTCBB: ADXS), a developer of live cancer vaccines based upon modified, attenuated Listeria monocytogenes, today announced a new...
PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 3, 2005--Advaxis, Inc. (OTCBB: ADXS), a developer of Listeria monocytogenes based cancer vaccines, will be presenting at the Rodman and Renshaw Techvest 7th...
PRINCETON, N.J.--(BUSINESS WIRE)--Oct. 10, 2005--Advaxis (OTCBB: ADXS), today issued the following clarifications regarding the role that its product candidate Lovaxin C may eventually play in the...
PRINCETON, N.J.--(BUSINESS WIRE)--Sept. 26, 2005--Advaxis, Inc. (OTCBB: ADXS) today announced that a significant publication of work performed by Dr. Yvonne Paterson, scientific founder of Advaxis,...
PRINCETON, N.J.--(BUSINESS WIRE)--Aug. 29, 2005--Advaxis, Inc. (OTCBB: ADXS) announced today that it has successfully completed its pre-clinical toxicology studies of Lovaxin C, its Listeria Cancer...
